Abstract:Introduction: Upregulated telomerase activity is an established hallmark in about 85-90% of cancer malignancies making it an attractive therapeutic target. However, the development of approved small-molecule telomerase inhibitors has been impeded by a lack of structural ambiguity for decades. In our study, we have employed a molecular dynamics approach to validate the binding site of BIBR1532, an approved telomerase inhibitor in the hTERT thumb domain followed by a structure-based drug designing approach to repurpose FDA-approved drugs and identify novel lead compounds targeting the enzyme. Material and Methods: Due to the unavailability of a co-crystalized structure of BIBR1532 with the catalytic hTERT thumb domain, we employed a Molecular dynamics-based method to identify and validate the exact binding site of the inhibitor. Two pharmacophore models were generated for the putative and newly identified binding pockets which were screened virtually through an anti-cancer library and Drug Bank database. The models were validated on the basis of the fit value of the BIBR1532 and selectivity value indicating the favorable feature set required. The top hits obtained were filtered using drug-likeliness parameters like Lipinski, ADME, and TOPKAT followed by redocking into their binding site. Finally, lead molecules that were able to dock in the new pocket were validated using Molecular Dynamics (MD)simulation studies and their binding free energy was calculated using MM-PBSA calculations followed by their evaluation using in-vitro TRAP assay. Results: Structural investigation, molecular docking studies, and confirmatory molecular dynamics revealed that the exact binding site of BIBR1532 is 8.4 Å away from the reported FVYL pocket strikingly with clinically relevant and characteristic interactions conserved. We have identified five lead compounds and four lead compounds from DrugBank and the anti-cancer library respectively, that were stable in the new binding pocket based on their MD trajectory analysis, and parameters like RMSD, RMSF, H-bonds and Radius of Gyration as well as their MM-PBSA scores. The lead compounds are being evaluated in vitro using TRAP assay and ex-vivo assays. Conclusion: The study identified five existing FDA-approved drugs in the market for other diseases as potential telomerase inhibitors alongside four novel compounds that can be used for the treatment of cancer in the future after further validation studies. Citation Format: Divpreet Kaur, Madhu Chopra, Daman Saluja. Identification of novel lead compounds and repurposing FDA approved drugs as telomerase inhibitors using structure-based drug designing approach and their evaluation using in-vitro and ex-vivo assays [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 4485.

Design, synthesis and SARs of novel telomerase inhibitors based on BIBR1532

Design, Synthesis and Biological Evaluation of Heterocyclic Azoles Derivatives Containing Pyrazine Moiety As Potential Telomerase Inhibitors

Synthesis, Biological Evaluation, 3D-QSAR Studies of Novel Aryl-2H-pyrazole Derivatives As Telomerase Inhibitors.

Synthesis, Molecular Modeling and Biological Evaluation of N-benzylidene-2-((5-(pyridin-4-yl)-1,3,4-oxadiazol-2-yl)thio)acetohydrazide Derivatives As Potential Anticancer Agents

Ethenesulfonyl Fluoride Derivatives As Telomerase Inhibitors: Structure-Based Design, SAR, and Anticancer Evaluation in Vitro

Design and Synthesis of Novel 2-Methyl-4,5-substitutedbenzo[f]-3,3a,4,5-tetrahydro-pyrazolo[1,5-d][1,4]oxazepin-8(7h)-one Derivatives As Telomerase Inhibitors

Synthesis, biological evaluation, and molecular docking studies of 1,3,4-oxadiazole derivatives possessing 1,4-benzodioxan moiety as potential anticancer agents.

Design and Synthesis of Novel 5-Phenyl-n-piperidine Ethanone Containing 4,5-Dihydropyrazole Derivatives As Potential Antitumor Agents.

Novel Coumarin-Dihydropyrazole Thio-Ethanone Derivatives: Design, Synthesis and Anticancer Activity.

Synthesis and Molecular Docking Studies of Novel 2-Chloro-pyridine Derivatives Containing Flavone Moieties As Potential Antitumor Agents.

Synthesis and Biological Evaluation of Quinoline–imidazole Hybrids As Potent Telomerase Inhibitors: a Promising Class of Antitumor Agents

Design and Synthesis of N-phenylacetyl (sulfonyl) 4,5-Dihydropyrazole Derivatives As Potential Antitumor Agents.

Synthesis and Molecular Docking Study of Novel Coumarin Derivatives Containing 4,5-Dihydropyrazole Moiety As Potential Antitumor Agents

Design, synthesis, biological evaluation and docking study of novel quinazoline derivatives as EGFR-TK inhibitors

Synthesis, biological evaluation, and molecular docking studies of pyrazolyl-acylhydrazone derivatives as novel anticancer agents

Design, synthesis and antitumor activity of novel thiophene-pyrimidine derivatives as EGFR inhibitors overcoming T790M and L858R/T790M mutations

Abstract 4485: Identification of novel lead compounds and repurposing FDA approved drugs as telomerase inhibitors using structure-based drug designing approach and their evaluation using in-vitro and ex-vivo assays

Synthesis, Molecular Modeling and Biological Evaluation of 2-Aminomethyl-5-(quinolin-2-yl)-1,3,4-oxadiazole-2(3h)-thione Quinolone Derivatives As Novel Anticancer Agent

4,5-Dihydropyrazole derivatives containing oxygen-bearing heterocycles as potential telomerase inhibitors with anticancer activity

Novel 3-(2-(3-methyl-5-substituted-phenyl-4,5-dihydropyrazol-1-yl)-2-oxoethoxy)-2-substituted-phenyl-4H-chromen-4-one: synthesis and anticancer activity.

Novel 3-(1-acetyl-5-(substituted-phenyl)-4,5-dihydro-1h-pyrazol-3-yl)-7-fluoro-2h-chromen-2-one Derivatives: Synthesis and Anticancer Activity